Home

Friday, January 23, 2026

CME/CNE-accredited Conference

7:00 am - 4:00 pm EST

In-person
Hilton Philadelphia City Avenue, 4200 City Avenue, Philadelphia, PA, 19131

Register Now

Overview

This course is a comprehensive review of hematologic malignancies focusing on research developments over the preceding year and their application to the patient care journey. Didactic presentations will include case discussion with Penn faculty and community experts. Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care. Participants will leave with up-to-date, practical information which will have immediate clinical application.

Who Should Attend

This activity has been designed for hematologists, medical and radiation oncologists, primary care physicians, pathologists, hematology/oncology fellows, oncology nurses, oncology social workers, and other healthcare professionals involved in the treatment of patients with blood cancer.

Learning Objectives

At the completion of this course, participants should be able to:

  • Integrate novel targeted agents and combinations into evidence-based care plans for Follicular Lymphoma and CLL/SLL.
  • Evaluate optimal selection and sequencing of treatments for aggressive lymphomas in the relapsed/refractory setting.
  • Identify strategies to improve transplant access, including the use of mismatched donors in allogeneic and autologous settings.
  • Compare current and investigational approaches for the prevention and treatment of Graft-versus-Host Disease (GVHD).
  • Compare emerging and investigational treatments, including novel immunotherapies, for Acute Myeloid Leukemia (AML) and other Acute Leukemias.
  • Formulate diagnostic and management plans for MDS and MPNs, applying contemporary risk-stratification.
  • Assess best practices for the diagnosis and initial therapy of Smoldering Myeloma, Amyloidosis, and Newly Diagnosed Multiple Myeloma, including the role of transplant.
  • Evaluate the role and toxicity management of CAR T-cells and bispecific T-cell engagers in newly diagnosed and relapsed Multiple Myeloma.